Compare CTMX & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTMX | BBNX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 560.5M |
| IPO Year | 2015 | N/A |
| Metric | CTMX | BBNX |
|---|---|---|
| Price | $5.40 | $12.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $8.86 | ★ $26.73 |
| AVG Volume (30 Days) | ★ 2.9M | 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $138,103,000.00 | N/A |
| Revenue This Year | N/A | $35.03 |
| Revenue Next Year | N/A | $33.24 |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | ★ 36.45 | N/A |
| 52 Week Low | $0.40 | $8.89 |
| 52 Week High | $6.35 | $32.71 |
| Indicator | CTMX | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 29.44 |
| Support Level | $5.10 | $12.10 |
| Resistance Level | $6.25 | $15.64 |
| Average True Range (ATR) | 0.33 | 1.02 |
| MACD | -0.06 | 0.30 |
| Stochastic Oscillator | 33.18 | 27.38 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.